clinical-trial-matching
(4)
Inside the Atlanta Startup Rewiring How Cancer Gets Decided
OncoLens turned the tumor board - medicine's oldest committee - into AI-backed software now running inside 225-plus cancer centers. It started with a daughter watching her father get conflicting advice.
Leal Health
Leal Health (formerly TrialJectory) is an AI-powered treatment decision-support platform that gives cancer patients and their oncologists an unbiased, single point of access to FDA-approved therapies and clinical trials matched to a patient's exact diagnosis. Founded in 2017 and headquartered in New York, the company built a patented, generative-AI engine that reads thousands of trials and treatment options, then matches patients in a roughly two-minute intake. It has facilitated millions of treatment matches across 22+ cancer types, is free for patients and clinicians, and earns revenue from biopharma partners and health plans. In February 2026 Leal Health was acquired by Nexus Precision Health.
Triomics
Triomics builds oncology-specific AI infrastructure that turns messy, unstructured cancer patient records into structured, cited, actionable data. Its OncoLLM engine and workflow agents automate clinical trial matching, visit preparation, and cancer registry reporting for leading cancer centers, cutting manual chart review time while increasing trial enrollment. Founded in 2021 and headquartered in New York, the company is used by 4 of the top 10 U.S. cancer hospitals and raised a $22M Series B led by Battery Ventures in May 2026.
Tempus AI
Tempus AI is a Chicago-based health technology company that has built one of the world's largest libraries of clinical and molecular data, paired with an AI operating system that helps physicians and researchers make data-driven decisions in oncology, cardiology, radiology, and beyond. Founded in 2015 by Groupon co-founder Eric Lefkofsky after his wife's cancer diagnosis, the company sequences patient genomes, structures messy clinical records, and turns that data into diagnostics and AI tools used across a majority of U.S. academic medical centers. It went public on Nasdaq in June 2024 under the ticker TEM.